PE (sFlt-1/PlGF) Test (Serum)

The sFlt-1/PlGF ratio compares two pregnancy-related biomarkers linked with placental function. sFlt-1 is an anti-angiogenic protein mainly produced in the placenta, while PlGF, or placental growth factor, is a pro-angiogenic factor that supports placental blood vessel development. In pre-eclampsia, sFlt-1 levels are commonly increased and free PlGF levels are commonly reduced, making the ratio useful as an aid in pre-eclampsia risk evaluation.

The PE (sFlt-1/PlGF) Test (Serum) is intended for the professional in vitro diagnostic evaluation of the sFlt-1/PlGF ratio in human serum. It is used as an aid for pre-eclampsia risk assessment and risk stratification in pregnant women with suspected hypertensive disorders of pregnancy.

Applications

• Pre-eclampsia risk assessment
• Evaluation of suspected hypertensive disorders of pregnancy
• Maternal serum biomarker testing
• Risk stratification in prenatal care
• Support for maternity hospital workflows
• Gynecology clinic testing support
• Diagnostic laboratory reporting

The PE (sFlt-1/PlGF) Test (Serum) uses a fluorescence-based immunoassay method. Fluorescence immunoassay technology supports sensitive biomarker detection from serum samples and is commonly used in modern diagnostic platforms for quantitative or semi-quantitative clinical testing.

Benefits

• Fluorescence-based detection method
• Supports sensitive biomarker evaluation
• Suitable for serum specimen testing
• Useful for professional laboratory workflows
• Supports pre-eclampsia risk assessment
• Compatible with clinical diagnostic environments
• Designed for international healthcare markets

The correct specimen for the PE (sFlt-1/PlGF) Test is serum. Proper specimen collection, separation, storage, and handling are important for reliable test performance. The test should be performed only by trained healthcare or laboratory professionals according to the official product insert.

Guidance

• Use serum specimens only
• Collect blood using approved clinical collection procedures
• Separate serum according to laboratory protocol
• Avoid hemolyzed, contaminated, or improperly stored specimens
• Use compatible fluorescence analyzer systems where required
• Follow the LARKSOIS Pharma product insert carefully

Note

Incorrect specimen handling may affect test performance. Always follow validated laboratory procedures and local diagnostic guidelines.

Steps

• Bring the test device, serum sample, and reagents to the required testing temperature
• Open the sealed test package only when ready to perform the test
• Prepare the serum specimen according to the product insert
• Apply the required amount of serum or prepared sample to the test device
• Insert or process the test device using the compatible fluorescence analyzer system
• Allow the test reaction to complete within the instructed time
• Read and report the result according to the approved interpretation guidance

Note

The exact testing procedure may vary depending on the analyzer system and LARKSOIS Pharma product insert. Laboratory professionals should follow the official instructions supplied with the kit.

• The PE (sFlt-1/PlGF) Test is clinically useful because pre-eclampsia is associated with an imbalance between anti-angiogenic and pro-angiogenic placental factors. A higher sFlt-1/PlGF ratio may suggest increased pre-eclampsia risk, while a lower ratio may support lower short-term risk when interpreted with clinical findings.
• The test may help healthcare professionals classify patients into lower-risk or higher-risk groups when used alongside blood pressure measurement, urine protein evaluation, liver function tests, kidney function tests, platelet count, symptoms, ultrasound findings, and obstetric history.
• The result should always be interpreted by qualified healthcare professionals. The sFlt-1/PlGF ratio is an aid to risk assessment and does not independently confirm or exclude pre-eclampsia.

Positive

A higher sFlt-1/PlGF ratio may indicate increased risk of pre-eclampsia progression or placental dysfunction, depending on gestational age, clinical condition, and the validated cut-off used by the laboratory.

Negative

A lower sFlt-1/PlGF ratio may indicate lower short-term risk when interpreted with clinical findings, but it does not remove the need for medical follow-up if symptoms or risk factors are present.

Invalid

If the analyzer, control system, or test device indicates an invalid result, repeat testing should be performed according to the product insert and laboratory quality-control procedure.

Instructions

• Store according to the temperature stated on the product label
• Keep the test device sealed until use
• Protect from moisture and direct sunlight
• Do not use expired test devices
• Do not use damaged or contaminated packaging
• Use only compatible testing materials and analyzer systems
• Dispose of used materials according to laboratory safety rules

Instructions

• For professional in vitro diagnostic use only
• Not intended for home use
• Not a standalone diagnostic test for pre-eclampsia
• Not a replacement for clinical judgment
• Results should be used with standard clinical evaluation
• Clinical decisions should not rely only on the sFlt-1/PlGF ratio
• Use caution in special clinical situations such as multiple pregnancy or complex treatment conditions
• Healthcare providers should follow local pregnancy-care and diagnostic guidelines

LARKSOIS Pharma provides professional diagnostic solutions for hospitals, laboratories, clinics, and international healthcare markets. The PE (sFlt-1/PlGF) Test (Serum) is developed for clinical environments that require reliable support for pre-eclampsia biomarker testing and pregnancy-related risk assessment.

Advantages

• Fluorescence-based immunofluorescence method
• Serum specimen compatibility
• Supports pre-eclampsia risk assessment
• Useful for maternity hospitals and gynecology clinics
• Helps evaluate placental biomarker imbalance
• Suitable for professional laboratory workflows
• Supports faster clinical information in prenatal care
• Designed for international diagnostic markets